Clinical Trial Update: An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating Sonazoid and SonoVue in pre- and post-contrast ultrasound for focal liver lesions; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Lesions

Drugs mentioned

• Sonazoid (perflubutane)
• SonoVue (sulfur hexafluoride microbubbles)

Snippet

Sponsor: GE Healthcare | Conditions: Liver Lesions | Phase 3 | Status: COMPLETED | Results posted: 2018-08-27